Essential Premium

With a Thin IPO Calendar, Hedge Funds Are Zeroing In on Biopharma

A slow January IPO market has leaned on biopharma and life‑sciences issuers — several backed by hedge fund specialists — for the few deals getting done.

The Tiger Grandcub Who Outsmarted the AI Frenzy

While everyone chased Nvidia, Jay Kahn’s fledgling Flight Deck scored a 51.6 percent return by buying the “picks and shovels.”

Sponsored

ETFs: Growing Institutional Adoption

How Hiddenite, a Young Long‑Short Fund, Delivered a Second Straight Triple‑Digit Year

Ryan Packard, once an Institutional Investor Rising Star, has delivered a remarkable string of performance with concentrated global equity positions and a disciplined use of options.

Related Content

Robinhood Wants to Become the Schwab of the Millennial Generation

Jonathan Kandell

Robinhood’s Sole Hedge Fund Manager

Stephen Taub

The Elliott-Led Activist Skirmish With Salesforce Lured Hedge Fund Investors

Michelle Celarier

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram